Conjugated Via Claimed Linking Group, Bond, Chelating Agent, Or Coupling Agent (e.g., Conjugated To Proteinaceous Toxin Via Claimed Linking Group, Bond, Coupling Agent, Etc.) Patents (Class 424/179.1)
  • Patent number: 10443026
    Abstract: A polygonal scaffold includes at least three polyproline II (PPII) helix rods and at least three connectors. Each of the PPII helix rods is composed of a plurality of repeat units represented by Formula (i), and at least one of the PPII helix rods has at least one hydrogen atom of at least one of the repeat units being substituted by a first chemical handle for connecting a ligand. Each of the connectors is a divalent organic group, and every two of the PPII helix rods are connected by one of the connectors to form a closed ring. Therefore, with the uniform composition, the PPII helix rods have a stable helical structure under aqueous conditions, and a desired rigidity can be provided.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: October 15, 2019
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Sheng-Kai Wang, Cin-Hao Lin
  • Patent number: 10307488
    Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 4, 2019
    Assignee: UNIVERSITE FRANCOIS RABELAIS
    Inventors: Nicolas Joubert, Marie Claude Viaud-Massuard, Renaud Respaud
  • Patent number: 10307391
    Abstract: The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: June 4, 2019
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventor: Robert Yongxin Zhao
  • Patent number: 10265291
    Abstract: The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: April 23, 2019
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventor: Robert Yongxin Zhao
  • Patent number: 10215727
    Abstract: Embodiments of the invention are directed to a solid-state zinc sensor. A non-limiting example of the sensor includes a semiconductor substrate. The sensor can also include an assembly surface on the semiconductor substrate. The sensor can also include a zinc detection monolayer chemically bound to the assembly surface. The sensor can also include a power supply electrically connected to the semiconductor substrate.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: February 26, 2019
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Ali Afzali-Ardakani, Abram L. Falk, Bharat Kumar
  • Patent number: 10201615
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: February 12, 2019
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Patent number: 10159745
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: December 25, 2018
    Assignee: MedImmune, LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • Patent number: 10118966
    Abstract: The present invention provides a method for producing an anti-EGFR monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by Chinese hamster, transfecting GS knockout host cells CHO-CR-GS?/?, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the low immunogenicity CMAB009 antibody.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: November 6, 2018
    Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.
    Inventor: Weizhu Qian
  • Patent number: 10117947
    Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: November 6, 2018
    Assignees: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
  • Patent number: 9943615
    Abstract: Disclosed herein are nanoparticles and method for manufacturing the same. The nanoparticle is essentially composed of albumin and polyethylene glycol, wherein the albumin is covalently crosslinked with the polyethylene glycol.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: April 17, 2018
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN R.O.C
    Inventors: Su-Jung Chen, Chang-An Chen, Chung-Yen Li, Chu-Nian Cheng, Ming-Syuan Lin, Shu-Pei Chiu, Chih-Hsien Chang
  • Patent number: 9939447
    Abstract: Compositions, kits, and methods are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. The compositions can include a first reagent including a cleavage-inducing moiety and a first binding agent for a binding site that includes a post-translational modification of a target polypeptide.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 10, 2018
    Assignee: Monogram Biosciences, Inc.
    Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
  • Patent number: 9895450
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: February 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9884126
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9878041
    Abstract: A tissue adhesive including cyanoacrylate and polyethylene glycol (PEG), wherein the PEG remains a polyether and wherein the tissue adhesive is bioabsorbable. A tissue adhesive including cyanoacrylate bulk monomer and cyanoacrylate nanoparticles containing a therapeutic therein. A kit for applying tissue adhesive, including the tissue adhesive described above and an applicator. Methods of accelerating degradation of a cyanoacrylate tissue adhesive applying a tissue adhesive, closing an internal wound, administering a therapeutic to tissue, treating cancer, and preventing infection in a wound. Methods of method of making a bioabsorbable tissue adhesive and making a therapeutic tissue adhesive.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: January 30, 2018
    Assignee: Adhezion Biomedical, LLC
    Inventors: Jeoung Soo Lee, Charles Kenneth Webb, Robert Zimmerman, Rafael Ruiz, Sr., Sheng Zhang
  • Patent number: 9803002
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 31, 2017
    Assignee: Genentench, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9752137
    Abstract: Compounds, compositions and methods for the preparation of peptide/protein conjugates, said method comprising a step of reacting a compound (2) represented by the formula (2) with a compound (3) represented by the formula (3) to obtain compound (1) represented by the formula (1), wherein R? represents substituent, and R represents H or at least one substituents. Also disclosed is a kit comprising the compound.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: September 5, 2017
    Assignee: THE UNIVERSITY OF HONG KONG SHENZHEN INSTITUTE OF RESEARCH AND INNOVATION
    Inventors: Xuechen Li, Chun Ling Tung, Clarence Tsun Ting Wong
  • Patent number: 9688721
    Abstract: Tubulysin compounds of the formula (I) where R1, R2 R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: June 27, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qiang Cong, Heng Cheng, Sanjeev Gangwar
  • Patent number: 9675715
    Abstract: There is provided a contrast agent for photoacoustic imaging, the contrast agent exhibiting high tumor accumulation and high photoacoustic signal intensity even when time has passed since administration. A contrast agent for photoacoustic imaging comprises a complex including albumin covalently bound to an organic dye that absorbs light in the near-infrared wavelength region.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: June 13, 2017
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Atsushi Takahashi, Satoshi Ogawa, Fumio Yamauchi, Kengo Kanazaki, Daisuke Sasaguri, Masato Minami
  • Patent number: 9580495
    Abstract: Severe glomerulonephritis involves cell necrosis as well as NETosis, programmed neutrophil death leading to expulsion of nuclear chromatin and neutrophil extracellular traps (NETs). Histones released by neutrophils undergoing NETosis killed glomerular endothelial cells, podocytes, and parietal epithelial cells. This was prevented by histone-neutralizing agents anti-histone IgG, activated protein C and heparin. Histone toxicity on glomeruli was TLR2/4-dependent. Anti-GBM glomerulonephritis involved NET formation and vascular necrosis. Pre-emptive anti-histone IgG administration significantly reduced all aspects of glomerulonephritis, including vascular necrosis, podocyte loss, albuminuria, cytokine induction, recruitment and activation of glomerular leukocytes and glomerular crescent formation.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: February 28, 2017
    Assignee: Immunomedics, Inc.
    Inventors: Santhosh V. R. Kumar, Hans-Joachim Anders
  • Patent number: 9511140
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: December 6, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • Patent number: 9498541
    Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 22, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Ravi V. J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne C. Widdison
  • Patent number: 9493504
    Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with a radioisotope. The method of the invention is particularly suitable for use with an automated synthesizer apparatus. Also provided are precursors in sterile form, as well as cassettes comprising such precursors useful in the method.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: November 15, 2016
    Assignee: GE Healthcare Limited
    Inventor: Bard Indrevoll
  • Patent number: 9181235
    Abstract: The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R1, R2, R3 are as defined herein.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS AG
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan, Lichun Shen, Rajender Reddy Leleti
  • Patent number: 9102730
    Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 11, 2015
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 9044518
    Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: June 2, 2015
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: George R. Pettit, Fiona Hogan, Steven Toms
  • Publication number: 20150140022
    Abstract: A compound comprising a photosensitizer covalently coupled to a protein selected from the group consisting of antibodies or their derivatives or fragments thereof, synthetic peptides such as scFv, mimotopes which bind CD antigens, cytokine receptors, interleukin receptors, hormone receptors, growth factor receptors, more particularly tyrosine kinase growth factor receptor of the ErbB family, wherein the photosensitizer is coupled to the binding protein via O6-alkylguanine-DNA alkyltransferase (hAGTm), a modified human DNA repair protein.
    Type: Application
    Filed: March 21, 2012
    Publication date: May 21, 2015
    Inventors: Stefan Barth, Mehmet K. Tur, Ahmad Hussain
  • Publication number: 20150139947
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: October 31, 2014
    Publication date: May 21, 2015
    Applicant: BIOGEN IDEC HEMOPHILIA INC.
    Inventors: ROBERT T. PETERS, ADAM R. MEZO, DANIEL S. RIVERA, ALAN J. BITONI, SUSAN C. LOW
  • Publication number: 20150132324
    Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 14, 2015
    Inventors: Qiang CONG, Heng Cheng, Sanjeev Gangwar
  • Patent number: 9028833
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: May 12, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Publication number: 20150125474
    Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 7, 2015
    Inventors: Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
  • Publication number: 20150125473
    Abstract: The present invention concerns a process for the preparation of an antibody conjugate comprising the step of reacting an engineered antibody having a single inter-heavy chain disulfide bond with a conjugating reagent that forms a bridge between the two cysteine residues derived from the disulfide bond.
    Type: Application
    Filed: June 19, 2013
    Publication date: May 7, 2015
    Inventors: John Burt, Antony Godwin, George Badescu
  • Patent number: 9023356
    Abstract: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: May 5, 2015
    Assignees: Ludwig Institute for Cancer Research Ltd, The Regents of the University of California
    Inventors: Terrance Grant Johns, Webster Cavenee, Frank Furnari, Andrew Scott
  • Publication number: 20150118185
    Abstract: Compositions containing conjugates of heparosan polymer with at least one drug are disclosed, along with methods of production and use thereof.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 30, 2015
    Inventor: Paul L. DeAngelis
  • Publication number: 20150104468
    Abstract: The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.
    Type: Application
    Filed: May 31, 2013
    Publication date: April 16, 2015
    Applicant: IRM LLC
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Badry Bursulaya
  • Publication number: 20150104383
    Abstract: The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as described above and a pharmaceutically acceptable carrier. The invention further provides for methods of making the hybrid molecules, and methods of using the hybrid molecule described above to inhibit cell surface receptor binding.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventors: Christoph Rader, Thomas Hofer, Terrence R. Burke, JR., Joshua Thomas
  • Patent number: 9005625
    Abstract: The present invention provides conjugates formed between toxins and sugars and toxins and peptides, such as antibodies. In an exemplary embodiment, a toxin-sugar construct is conjugated to an antibody through an intact glycosyl linking group.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: April 14, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Zhi-Guang Wang
  • Patent number: 8992932
    Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: October 20, 2012
    Date of Patent: March 31, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte Christine Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jöriβen, Sandra Borkowski
  • Publication number: 20150086576
    Abstract: In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided. In some aspects, products and methods of use in modulating the immune system, e.g., modulating an immune response, are provided.
    Type: Application
    Filed: April 15, 2013
    Publication date: March 26, 2015
    Inventors: Hidde Ploegh, Maximilian Popp, Juanjo Cragnolini
  • Patent number: 8986699
    Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a carrier such as a polymer, nanoparticle, complex or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing cell death of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: March 24, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, David M. Goldenberg, Chien-Hsing Chang
  • Patent number: 8980824
    Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: March 17, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qiang Cong, Heng Cheng, Sanjeev Gangwar
  • Patent number: 8974792
    Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: March 10, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Marie Alix Poul
  • Patent number: 8968741
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: March 3, 2015
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • Publication number: 20150056223
    Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), including a conjugate prepared by covalently linking an insulinotropic peptide, a non-peptidyl polymer and an immunoglobulin Fc region. The composition of the present invention maintains the in-vivo activity of the peptide at a relatively high level, and remarkably increases the blood half-life, thereby preventing triglyceride accumulation which is a typical feature of non-alcoholic fatty liver disease. Ultimately, it can be desirably employed for the prevention and treatment of non-alcoholic fatty liver disease.
    Type: Application
    Filed: March 8, 2013
    Publication date: February 26, 2015
    Applicant: HANMI SCIENCE CO., LTD
    Inventors: Se Young Lim, Sung Hee Park, Ryoung Ae Shin, In Young Choi, Se Chang Kwon
  • Patent number: 8962805
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: February 24, 2015
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • Publication number: 20150044229
    Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 12, 2015
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
  • Publication number: 20150044237
    Abstract: New chimeric molecules involving in their structure, a combination of the extracellular domain (EC) of the FasL protein and a domain enabling oligomerisation of this Fas Ligand (FasL) EC domain, such as the Ig-like (so-called Ig in the following pages) domain of the gp190 receptor for the Leukemia Inhibitory Factor (LIF), or involving in their structure variants of the domains. Also, compositions including the chimeric molecule defined herein and the use of these chimeric molecules especially to trigger cytotoxic activity toward cells sensitive to FasL.
    Type: Application
    Filed: October 26, 2012
    Publication date: February 12, 2015
    Applicant: Centre National de la Recherche Scientifique
    Inventors: Jean-Luc Taupin, Sophie Daburon, Jean-Francois Moreau, Myriam Capone
  • Patent number: 8951532
    Abstract: The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: February 10, 2015
    Assignee: Alere Scarborough, Inc.
    Inventors: Brion Mermer, William J. Palin, Nancy Turcotte
  • Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Patent number: 8945571
    Abstract: The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: February 3, 2015
    Assignee: Roche GlyeArt AG
    Inventors: Ekkehard Mössner, Ralf Jörg Hosse, Pablo Umaña, Michela Silacci-Melkko
  • Publication number: 20150030594
    Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 29, 2015
    Applicant: NOVARTIS AG
    Inventors: Jun YUAN, Frederic ZECRI, Philipp GROSCHE, Hongjuan ZHAO, Andrei GOLOSOV, Kayo YASOSHIMA, David Thomas PARKER, Eric PETERS, Aimee Richardson USERA, Shari Lynn CAPLAN, Aaron KANTER, Changgang LOU, Carla Guimaraes